In IBD, CB1 acts to maintain the integrity of the epithelial barrier, and CB2 acts to inhibit macrophage cytokine production; new strains of engineered probiotic organisms, which generate endocannabinoid analogues, in conjunction with short-chain fatty acid (SCFA) supplementation, greatly increase effectiveness [68,218,219]. Here, CNR1 is linked to irritable bowel syndrome.